---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-148112"
form_type: "8-K"
ticker: "IMA"
cik: "0001835579"
company_name: "ImageneBio, Inc."
filed_at: "2024-05-28T23:59:59+00:00"
generated_at: "2026-06-01T08:16:25.984341+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Ikena Oncology discontinues IK-930, cuts workforce 53%, explores strategic options

## Summary
- Discontinued IK-930 (TEAD1 inhibitor) clinical development; winddown activities began.
- Reducing workforce by ~53% (18 employees); expected ~16 FTE remaining; cash costs ~$1.2M in Q2 2024.
- Continuing IK-595 (MEK-RAF glue) Phase 1; >80% pERK inhibition at 4h, >60% at 24h; dose escalation ongoing.
- Cash, equivalents and marketable securities $157.3M as of March 31, 2024.
- Board authorized exploration of strategic alternatives including acquisition, merger, sale, or partnership.

## SEC filing metadata
- accession: 0001193125-24-148112
- form_type: 8-K
- ticker: IMA
- cik: 0001835579
- company_name: ImageneBio, Inc.
- filed_at: 2024-05-28T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.05, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835579/000119312524148112/0001193125-24-148112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835579/000119312524148112/d817758d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-148112
- JSON: https://secwatch.observer/filing/0001193125-24-148112.json
- Plain text: https://secwatch.observer/filing/0001193125-24-148112.txt

## Key facts
- Restructurings & Charges
  ImageneBio, Inc. announced a restructuring with charges of approximately $1.2 million in cash expenditures affecting company-wide (clinical programs IK-930 and IK-595) (approximately 53%).
  - Type: restructuring
  - Charge: approximately $1.2 million in cash expenditures
  - Affected area: company-wide (clinical programs IK-930 and IK-595)
  - Headcount: approximately 53%
  source text: the Restructuring Plan during the three months ended June 30, 2024 related to employee severance and related termination benefits, which are expected to result in approximately $1.2 million in cash expenditures. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Ikena Oncology Announces Strategic Update Ikena to discontinue development of IK-930 IK-595 dose
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835579/000119312524148112/0001193125-24-148112-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.